Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab in mild to moderate Alzheimer's disease
NCT00112073Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2005
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Apr 2005; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00112073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112073.